CN1880304A - 三酰胺取代的吲哚、苯并呋喃及苯并噻吩 - Google Patents
三酰胺取代的吲哚、苯并呋喃及苯并噻吩 Download PDFInfo
- Publication number
- CN1880304A CN1880304A CNA2006100941142A CN200610094114A CN1880304A CN 1880304 A CN1880304 A CN 1880304A CN A2006100941142 A CNA2006100941142 A CN A2006100941142A CN 200610094114 A CN200610094114 A CN 200610094114A CN 1880304 A CN1880304 A CN 1880304A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- methyl
- trifluoromethyl
- compound
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
Description
表12 | |||
2-θ角(/°) | 强度(/%) | 2-θ角(/°) | 强度(/%) |
5.673 | 100.00 | 25.654 | 9.48 |
11.359 | 8.38 | 25.699 | 2.71 |
12.848 | 23.61 | 25.767 | 5.84 |
13.354 | 8.19 | 25.862 | 2.18 |
13.930 | 8.67 | 26.425 | 2.02 |
14.091 | 3.57 | 26.665 | 3.22 |
15.374 | 3.21 | 26.894 | 2.36 |
15.750 | 3.88 | 27.054 | 4.25 |
16.668 | 16.53 | 27.556 | 7.66 |
17.501 | 5.36 | 27.983 | 2.97 |
17.691 | 6.87 | 28.071 | 7.04 |
17.790 | 5.31 | 28.547 | 5.53 |
18.073 | 2.47 | 28.763 | 3.60 |
18.886 | 2.17 | 28.771 | 3.31 |
19.361 | 42.54 | 29.351 | 10.87 |
19.363 | 26.18 | 29.578 | 5.76 |
19.575 | 3.55 | 29.983 | 8.44 |
19.633 | 2.40 | 30.830 | 8.48 |
19.922 | 3.34 | 31.115 | 9.03 |
20.103 | 15.17 | 31.746 | 4.06 |
20.216 | 2.38 | 31.807 | 3.79 |
21.352 | 5.08 | 32.401 | 2.28 |
21.417 | 6.47 | 32.540 | 3.47 |
22.022 | 5.00 | 33.326 | 2.08 |
22.750 | 14.75 | 33.802 | 2.28 |
22.817 | 6.19 | 36.240 | 3.98 |
22.832 | 2.63 | 37.491 | 2.71 |
23.948 | 6.50 | 38.312 | 2.03 |
23.954 | 5.24 | 38.360 | 4.67 |
24.322 | 2.66 | 39.406 | 2.45 |
24.399 | 3.20 | 39.752 | 3.11 |
24.471 | 5.84 | 40.510 | 2.81 |
24.681 | 2.98 | 43.483 | 2.17 |
24.761 | 21.22 |
7 | H | 乙基 | 乙基 | 612.658 | 613.2 | 15.158 |
8 | 乙基 | H | 异丙基甲基 | 640.712 | 641.2 | 17.318 |
9 | 乙基 | 甲基 | 苄基 | 688.756 | 689.2 | 19.712 |
10 | 乙基 | 甲基 | 丙基 | 640.712 | 641.2 | 18.505 |
11 | 乙基 | 吡咯烷-1-基 | 638.696 | 639.2 | 16.558 | |
12 | H | H | 丙基 | 598.63 | 599.2 | 13.357 |
13 | H | H | 环丙基甲基 | 610.642 | 611.2 | 13.741 |
14 | 苄基 | H | 异丙基甲基 | 702.783 | 703.2 | 19.25 |
15 | 丙基 | H | 苄基 | 688.756 | 689.2 | 24.897 |
16 | H | 吡咯烷-1-基 | 610.642 | 611.2 | 13.337 | |
17 | H | 甲基 | 吡啶-3-基甲基 | 661.69 | 662.2 | 5.671 |
18 | 甲基 | 甲基 | 吡啶-3-基甲基 | 675.717 | 676.2 | 7.099 |
19 | 苄基 | 甲基 | 吡啶-3-基甲基 | 751.816 | 752.2 | 16.229 |
20 | 乙基 | H | 3-甲基-苄基 | 688.756 | 689.2 | 18.511 |
21 | 苄基 | H | 3-甲基-苄基 | 750.828 | 751.2 | 20.242 |
22 | 苄基 | H | 2-苯基-丙-2-基 | 764.855 | 765.2 | 21.217 |
23 | 苄基 | H | 4-甲基-苄基 | 750.828 | 751.2 | 20.209 |
24 | 甲基 | H | 4-氟-苄基 | 678.693 | 679.2 | 16.585 |
39 | 甲基 | H | 苄基 | 661.69 | 662.8 | 12.95 |
40 | 甲基 | 吗啉-4-基 | 641.65 | 642.5 | 9.72 | |
41 | 甲基 | 吡咯烷-1-基 | 625.65 | 626.5 | 11.44 | |
42 | 甲基 | 甲基 | 吡啶-3-基 | 676.70 | 677.5 | 3.72 |
43 | 甲基 | H | 4-羧酸甲酯 | 719.73 | 720.8 | 12.10 |
49 | 甲基 | H | 甲基 | 吡啶-3-基 | H | 三氟甲基 | 710.16 | 710.2 | 8.513 |
50 | 甲基 | H | H | 丙基 | H | 三氟甲基 | 647.10 | 647.2 | 16.67 |
51 | 甲基 | H | 乙基 | 苄基 | H | 三氟甲基 | 723.20 | 723.2 | 21.392 |
52 | 甲基 | H | 甲基 | 3-氯-苄基 | H | 三氟甲基 | 743.61 | 744.2 | 20.578 |
53 | 甲基 | H | 甲基 | 苄基 | 甲基 | 三氟甲基 | 723.20 | 723.2 | 21.202 |
54 | 甲基 | H | H | 乙基 | 甲基 | 三氟甲基 | 647.10 | 647.2 | 15.615 |
55 | 甲基 | H | H | 异丙基 | 甲基 | 三氟甲基 | 661.1 | 661.2 | 17.161 |
56 | 甲基 | H | 甲基 | 吡啶-3-基 | 甲基 | 三氟甲基 | 724.18 | 724.2 | 9.154 |
57 | H | H | 甲基 | 苄基 | H | 三氟甲基 | 695.14 | 695.2 | 19.131 |
58 | 乙基 | H | 甲基 | 苄基 | H | 三氟甲基 | 723.20 | 723.2 | 21.172 |
59 | 乙基 | H | H | 4-甲氧基-苄基 | H | 三氟甲基 | 739.20 | 739.2 | 18.345 |
60 | 甲基 | 甲基 | 甲基 | 苄基 | H | 三氟甲基 | 709.22 | 709.2 | 8.966 |
61 | 甲氧基甲基 | H | 甲基 | 苄基 | H | 三氟甲基 | 739.20 | 739.2 | 19.677 |
62 | 甲基 | H | H | 丙基 | H | H | 579.10 | 579.2 | 14.388 |
63 | 甲基 | H | H | 异丙基 | H | H | 579.10 | 579.2 | 14.327 |
64 | 甲基 | H | 甲基 | 吡啶-2-基 | H | H | 642.16 | 642.2 | 11.303 |
65 | 甲基 | H | 甲基 | 吡啶-3-基 | H | H | 642.16 | 642.2 | 6.322 |
65b | 甲基 | H | 甲基 | 乙基 | H | 三氟甲基 | 633.12 | 633.2 | 4.318 |
65c | 甲基 | H | H | 4-甲基-苄基 | H | 三氟甲基 | 695.19 | 695.2 | 11.147 |
65d | 甲基 | H | H | 丙基 | H | 三氟甲基 | 633.12 | 633.2 | 6.923 |
65e | 甲基 | H | 乙基 | 乙基 | H | 三氟甲基 | 647.15 | 647.2 | 5.071 |
65f | 甲基 | H | H | 甲基 | H | 三氟甲基 | 605.06 | 605.2 | 5.433 |
实施例 | R1 | 分子量(计算值) | MS(实测值) | HPLC(min) |
113 | 异丙基甲基 | 524.668 | 525.2 | 14.958 |
114 | 2-甲氧基-苯基 | 560.658 | 561.2 | 15.07 |
115 | 2-甲基-5-氯-苯基 | 579.104 | 579.2 | 16.683 |
116 | 1-羟基-环丙-1-基 | 552.679 | 553.2 | 13.013 |
117 | 2-甲基-4-氯-苯基 | 579.104 | 579.2 | 16.651 |
118 | (降冰片-2-基)-甲基 | 562.718 | 563.2 | 17.288 |
119 | 环丁基 | 508.625 | 509.2 | 11.734 |
120 | 苯氧基-乙基-甲基 | 588.712 | 589.2 | 17.118 |
121 | 5-溴-呋喃-2-基 | 599.489 | 600.2 | 14.651 |
122 | 1-苯基-环戊-1-基 | 598.751 | 599.2 | 18.913 |
123 | 萘-1-基 | 580.692 | 581.2 | 15.995 |
124 | 3-氯-噻吩-2-基 | 571.102 | 571.2 | 15.847 |
125 | 全氟乙基 | 572.539 | 573.2 | 16.771 |
126 | 2-(吡咯-1-基)-苯基 | 595.707 | 596.2 | 15.497 |
127 | 异喹啉-1-基 | 581.68 | 582.2 | 16.432 |
填料/稀释剂 | 崩解剂/润湿剂 | 甜味剂 | 润滑剂 |
微晶纤维素/甘露醇1∶2(93.5%) | Ac-Di-Sol 3% | - | 硬脂酸镁1% |
甘露醇/Dcp 2∶1(93.5%) | Ac-Di-Sol 3% | - | 硬脂酸镁1% |
甘露醇/Dcp 2∶1(93.5%) | Ac-Di-Sol 3% | - | 硬脂酸镁1% |
甘露醇/Fast Flo乳糖1∶2(93.5%) | Ac-Di-Sol 3% | - | 硬脂酸镁1% |
微晶纤维素/甘露醇1∶2(73.5%) | Ac-Di-Sol 3% | (啤)酒酵母20% | 硬脂酸镁1% |
甘露醇/Dcp 2∶1(73.5%) | Ac-Di-Sol 3% | (啤)酒酵母20% | 硬脂酸镁1% |
微晶纤维素/甘露醇1∶2(92.5%) | Ac-Di-Sol 3%+Sls 1% | - | 硬脂酸镁1% |
微晶纤维素/甘露醇1∶2(72.5%) | Ac-Di-Sol 3%+Sls 1% | (啤)酒酵母20% | 硬脂酸镁1% |
微晶纤维素/甘露醇1∶2(92.5%) | Explotab4% | - | 硬脂酸镁1% |
微晶纤维素/甘露醇1∶2(93.5%) | Ac-Di-Sol 3% | - | 十八烷基富马酸钠1% |
甘露醇/Dcp 2∶1(62.5%) | Ac-Di-Sol 3%Sls=1% | 酵母提取物10%(啤)酒酵母20% | 硬脂酸镁1% |
商标 | 化学组成 | 商业来源 |
Triacetin | 三乙酸甘油酯 | Abitec |
Capmul CMC | 辛酸/癸酸甘油酯 | Abitec |
Miglyol 812 | 癸酸/琥珀酸甘油三酯 | Condea |
Miglyol 829 | aprylate/癸酸/琥珀酸甘油三酯 | Condea |
Miglyol 840 | 二辛酸/二癸酸丙二醇酯 | Condea |
Labrafil M 1944CS | 油酰聚二乙醇-6-甘油酯 | Gattefosse |
Maisine 35-1 | Glyceryl monolinoate | Gattefosse |
Peceol | 甘油单油酸酯 | Gattefosse |
Captex 355 EP | 中链甘油三酯 | Abitec |
Crodamol GTC/C | 中链甘油三酯 | Croda |
Labrafac CC | 中链甘油三酯 | Gattefosse |
Claims (15)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30164401P | 2001-06-28 | 2001-06-28 | |
US60/301,644 | 2001-06-28 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN028130219A Division CN1522246B (zh) | 2001-06-28 | 2002-05-24 | 三酰胺取代的吲哚、苯并呋喃及苯并噻吩 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1880304A true CN1880304A (zh) | 2006-12-20 |
CN1880304B CN1880304B (zh) | 2010-11-24 |
Family
ID=23164253
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN028130219A Expired - Fee Related CN1522246B (zh) | 2001-06-28 | 2002-05-24 | 三酰胺取代的吲哚、苯并呋喃及苯并噻吩 |
CN2006100941142A Expired - Fee Related CN1880304B (zh) | 2001-06-28 | 2002-05-24 | 三酰胺取代的吲哚、苯并呋喃及苯并噻吩 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN028130219A Expired - Fee Related CN1522246B (zh) | 2001-06-28 | 2002-05-24 | 三酰胺取代的吲哚、苯并呋喃及苯并噻吩 |
Country Status (47)
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103880797A (zh) * | 2014-03-26 | 2014-06-25 | 沈阳大学 | 苯并呋喃类化合物及其医药用途 |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60144284D1 (de) | 2000-11-01 | 2011-05-05 | Millennium Pharm Inc | Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung |
TNSN03146A1 (fr) * | 2001-06-28 | 2005-12-23 | Pfizer Prod Inc | Indoles, benzofurannes et benzothiophenes a substituant triamide, utiles comme inhibiteurs de secretion de la proteine de transfert des triglycerides microsomaux et/ou de l'apolipo-proteine b (apo b). |
WO2003057175A2 (en) * | 2002-01-02 | 2003-07-17 | Visen Medical, Inc. | Amine functionalized superparamagnetic nanoparticles for the synthesis of bioconjugates and uses therefor |
CA2515368A1 (en) * | 2003-02-13 | 2004-08-26 | Luciano Rossetti | Regulation of food intake and glucose production by modulation of long-chain fatty acyl-coa levels in the hypothalamus |
EP1631269A4 (en) * | 2003-05-20 | 2007-09-12 | Erimos Pharmaceutical Llp | METHODS AND COMPOSITIONS FOR THE ADMINISTRATION OF CATECHOLIC BUTANAS FOR THE TREATMENT OF OBESITY |
EP1636592B1 (en) | 2003-06-19 | 2012-12-19 | Merck Serono SA | Use of prion conversion modulating agents |
EP1696887A1 (en) * | 2003-11-14 | 2006-09-06 | Pfizer Products Inc. | Solid amorphous dispersions of an mtp inhibitor for treatment of obesity |
CA2555133A1 (en) | 2004-02-04 | 2005-09-01 | Pfizer Products Inc. | Substituted quinoline compounds |
US7932268B2 (en) | 2004-03-05 | 2011-04-26 | The Trustees Of The University Of Pennsylvania | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects |
FR2873694B1 (fr) * | 2004-07-27 | 2006-12-08 | Merck Sante Soc Par Actions Si | Nouveaux aza-indoles inhibiteurs de la mtp et apob |
WO2006041922A2 (en) * | 2004-10-08 | 2006-04-20 | Dara Biosciences, Inc. | Agents and methods for administration to the central nervous system |
PA8660701A1 (es) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
US20070026079A1 (en) * | 2005-02-14 | 2007-02-01 | Louis Herlands | Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels |
EP1890767A2 (en) * | 2005-05-27 | 2008-02-27 | Pfizer Products Inc. | Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss |
US7417066B2 (en) | 2005-06-08 | 2008-08-26 | Schering Ag | Inhibitors of soluble adenylate cyclase |
DE102005027274A1 (de) * | 2005-06-08 | 2006-12-14 | Schering Ag | Inhibitoren der löslichen Adenylatzyklase |
JP2009503050A (ja) * | 2005-08-04 | 2009-01-29 | ファイザー・リミテッド | ピペリジノイル−ピロリジンおよびピペリジノイル−ピペリジン化合物 |
JP2009511635A (ja) * | 2005-10-18 | 2009-03-19 | エージェリオン ファーマシューティカルズ | 哺乳動物における高脂血症に関連する障害を治療するための方法 |
US7741317B2 (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
US20090111778A1 (en) * | 2005-11-18 | 2009-04-30 | Richard Apodaca | 2-Keto-Oxazoles as Modulators of Fatty Acid Amide Hydrolase |
US7888376B2 (en) | 2005-11-23 | 2011-02-15 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
US9913917B2 (en) | 2005-12-22 | 2018-03-13 | Visen Medical, Inc. | Biocompatible fluorescent metal oxide nanoparticles |
US8383660B2 (en) | 2006-03-10 | 2013-02-26 | Pfizer Inc. | Dibenzyl amine compounds and derivatives |
US7645789B2 (en) | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
DK2674428T3 (en) * | 2006-04-07 | 2016-04-18 | Vertex Pharma | Modulators of ATP binding cassette transporters |
US10022352B2 (en) | 2006-04-07 | 2018-07-17 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
AU2007320906A1 (en) | 2006-11-13 | 2008-05-22 | Pfizer Products Inc. | Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof |
ES2382009T3 (es) | 2006-12-01 | 2012-06-04 | Bristol-Myers Squibb Company | Derivados de N-((3-bencil)-2,2-(bis-fenil-)-propan-1-amina como inhibidores de CETP para el tratamiento de aterosclerosis y enfermedades cardiovasculares |
WO2008079398A1 (en) * | 2006-12-21 | 2008-07-03 | Aegerion Pharmaceuticals, Inc. | Methods for treating obesity with a combination comprising a mtp inhibitor and a cholesterol absorption inhibitor |
ES2670852T3 (es) | 2007-02-09 | 2018-06-01 | Visen Medical, Inc. | Colorantes con policiclo y uso de los mismos |
WO2008100423A1 (en) * | 2007-02-09 | 2008-08-21 | Sirtris Pharmaceuticals, Inc. | Gut microsomal triglyceride transport protein inhibitors |
EP2155643B1 (en) | 2007-06-08 | 2016-08-10 | MannKind Corporation | Ire-1a inhibitors |
WO2009014674A1 (en) * | 2007-07-23 | 2009-01-29 | Sirtris Pharmaceuticals, Inc. | Heterocyclylamides as gut microsomal triglyceride transport protein inhibitors |
US20100286200A1 (en) * | 2008-01-16 | 2010-11-11 | Janssen Pharmaceutica Nv | Combination of metformin and an mtp inhibitor |
US20090197947A1 (en) * | 2008-02-01 | 2009-08-06 | The Research Foundation Of State University Of New York | Medicaments and methods for lowering plasma lipid levels and screening drugs |
JP5711151B2 (ja) * | 2010-01-06 | 2015-04-30 | 武田薬品工業株式会社 | インドール誘導体 |
US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
RU2569678C2 (ru) | 2010-04-22 | 2015-11-27 | Вертекс Фармасьютикалз Инкорпорейтед | Способ получения циклоалкилкарбоксамидо-индольных соединений |
EP2665708A4 (en) * | 2011-01-20 | 2014-07-09 | Univ Colorado Regents | MODULATORS OF THE TLR3 / DSRNA COMPLEX AND APPLICATIONS THEREOF |
CN102108070B (zh) * | 2011-01-26 | 2013-05-22 | 上海优贝德生物医药有限公司 | 5-氨基苯并呋喃-2-甲酸酯及其中间体的制备方法 |
EP2872122A1 (en) | 2012-07-16 | 2015-05-20 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof |
EP2963013A4 (en) | 2013-02-27 | 2016-09-14 | Shionogi & Co | INDOLE AND AZAINDOLE DERIVATIVES HAVING AMPK ACTIVATION ACTIVITY EACH |
WO2015121877A2 (en) * | 2014-02-17 | 2015-08-20 | Hetero Research Foundation | Polymorphs of lomitapide and its salts |
PL3424534T3 (pl) | 2014-04-15 | 2021-11-22 | Vertex Pharmaceuticals Incorporated | Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy mukowiscydozowy przezbłonowy regulator przewodnictwa |
CN112279808B (zh) | 2014-10-06 | 2024-03-08 | 弗特克斯药品有限公司 | 囊性纤维化跨膜转导调节因子调节剂 |
WO2017173274A1 (en) | 2016-03-31 | 2017-10-05 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
PE20191147A1 (es) | 2016-09-30 | 2019-09-02 | Vertex Pharma | Modulador de regulador de conductancia de transmembrana de fibrosis quistica, composiciones farmaceuticas, metodos de tratamiento y proceso para producir el modulador |
SG10201913606VA (en) | 2016-12-09 | 2020-02-27 | Vertex Pharma | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
CA3066084A1 (en) | 2017-06-08 | 2018-12-13 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
WO2019018395A1 (en) | 2017-07-17 | 2019-01-24 | Vertex Pharmaceuticals Incorporated | METHODS OF TREATING CYSTIC FIBROSIS |
ES2912657T3 (es) | 2017-08-02 | 2022-05-26 | Vertex Pharma | Procesos para preparar compuestos de pirrolidina |
US10654829B2 (en) | 2017-10-19 | 2020-05-19 | Vertex Pharmaceuticals Incorporated | Crystalline forms and compositions of CFTR modulators |
MX2020005753A (es) | 2017-12-08 | 2020-08-20 | Vertex Pharma | Procesos para producir moduladores de regulador de conductancia transmembranal de fibrosis quistica. |
TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
WO2019200246A1 (en) | 2018-04-13 | 2019-10-17 | Alexander Russell Abela | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
CN112608271A (zh) * | 2020-11-26 | 2021-04-06 | 安润医药科技(苏州)有限公司 | 酰胺衍生物及其在制备ep4受体拮抗剂中的应用 |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4022900A (en) | 1970-09-09 | 1977-05-10 | Marion Laboratories, Inc. | Compositions containing 1,2,3,4-tetrahydroisoquinolines used as hypotensive agents |
US4397855A (en) | 1981-06-26 | 1983-08-09 | Warner-Lambert Company | 4-(Substituted)-α, α-dimethyl-1-piperazine pentanoic acids and derivatives as anti-arteriosclerotic agents and method |
US4647576A (en) * | 1984-09-24 | 1987-03-03 | Warner-Lambert Company | Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis |
US5416009A (en) | 1991-01-23 | 1995-05-16 | The United States Of America | Nucleotide molecule encoding a specific Onchocerca volvulus antigen for the immunodiagnosis of onchocerciasis |
CA2091102C (en) | 1992-03-06 | 2009-05-26 | John R. Ii Wetterau | Microsomal triglyceride transfer protein |
US5595872A (en) | 1992-03-06 | 1997-01-21 | Bristol-Myers Squibb Company | Nucleic acids encoding microsomal trigyceride transfer protein |
GB9225141D0 (en) | 1992-12-01 | 1993-01-20 | Smithkline Beecham Corp | Chemical compounds |
US5739135A (en) | 1993-09-03 | 1998-04-14 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
FR2723739B1 (fr) * | 1994-08-19 | 1997-02-14 | Sanofi Sa | Derives de glycinamide, procedes pour leur preparation et medicaments les contenant. |
WO1996040640A1 (en) * | 1995-06-07 | 1996-12-19 | Pfizer Inc. | BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION |
MX9709914A (es) | 1995-06-07 | 1998-03-31 | Pfizer | Derivados de acido bifenil-2-carboxilico-tetrahidro-isoquinolin-6-ilo, su preparacion y el uso de los mismos. |
ES2191706T3 (es) | 1995-06-07 | 2003-09-16 | Pfizer | Derivados de tetrahidro-isoquinolinil-6-il amida del acido bifenil-2-carboxilico, su preparacion y su uso como inhibidores de la proteina de transferencia de trigliceridos microsomal y/o secrecion de apolipoproteina b (apo b). |
JP2000505360A (ja) | 1996-02-02 | 2000-05-09 | ブリギッテ メリット | 塑性的な材料から成るストランドを加工するための装置 |
US5827875A (en) | 1996-05-10 | 1998-10-27 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
EP0944602A1 (en) | 1996-11-27 | 1999-09-29 | Pfizer Inc. | Apo b-secretion/mtp inhibitory amides |
WO1998027979A1 (en) | 1996-12-20 | 1998-07-02 | Bristol-Myers Squibb Company | Heterocyclic inhibitors of microsomal triglyceride transfer protein and method |
US6066653A (en) | 1997-01-17 | 2000-05-23 | Bristol-Myers Squibb Co. | Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs |
US5968950A (en) | 1997-06-23 | 1999-10-19 | Pfizer Inc | Apo B-secretion/MTP inhibitor hydrochloride salt |
TW460478B (en) * | 1997-08-15 | 2001-10-21 | Chugai Pharmaceutical Co Ltd | Phenethylamine derivatives |
JP2959765B2 (ja) | 1997-12-12 | 1999-10-06 | 日本たばこ産業株式会社 | 3−ピペリジル−4−オキソキナゾリン誘導体及びそれを含有してなる医薬組成物 |
DE69829879T2 (de) | 1997-12-24 | 2006-03-02 | Sanofi-Aventis Deutschland Gmbh | Indolderivate als faktor xa inhibitoren |
EP1080724A4 (en) | 1998-05-22 | 2004-06-23 | Nippon Shinyaku Co Ltd | COMPOSITIONS FOR REDUCING MTP ACTIVITY |
CA2319495A1 (en) | 1998-06-08 | 1999-12-16 | Advanced Medicine, Inc. | Multibinding inhibitors of microsomal triglyceride transferase protein |
CO5090829A1 (es) * | 1998-07-21 | 2001-10-30 | Novartis Ag | Compuestos organicos de la formula i, utiles como inhibido res de la proteina de transferencia de triglicerido microso mal y de la secrecion de la apolipoproteina b. |
US6197798B1 (en) | 1998-07-21 | 2001-03-06 | Novartis Ag | Amino-benzocycloalkane derivatives |
CA2375920A1 (en) * | 1999-06-14 | 2000-12-21 | Eli Lilly And Company | Compounds |
DE19933926A1 (de) | 1999-07-20 | 2001-01-25 | Boehringer Ingelheim Pharma | Biphenylderivate, ihre Herstellung und ihre Verwendung als Arzneimittel |
DE19945594A1 (de) * | 1999-09-23 | 2001-03-29 | Boehringer Ingelheim Pharma | Substituierte Piperazinderivate, ihre Herstellung und ihre Verwendung als Arzneimittel |
CA2325358C (en) * | 1999-11-10 | 2005-08-02 | Pfizer Products Inc. | 7-¬(4'-trifluoromethyl-biphenyl-2-carbonyl)amino|-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein b |
DE19963234A1 (de) | 1999-12-27 | 2002-01-24 | Boehringer Ingelheim Pharma | Substituierte Piperazinderivate, ihre Herstellung und ihre Verwendung als Arzneimittel |
DE19963235A1 (de) * | 1999-12-27 | 2001-07-05 | Boehringer Ingelheim Pharma | Substituierte Piperazinderivate, ihre Herstellung und ihre Verwendung als Arzneimittel |
ES2240420T3 (es) | 2000-01-18 | 2005-10-16 | Novartis Ag | Carboxamidas utiles como inhibidores de la proteina de transferencia de trigliceridos microsomicos y de la secrecion de apolipoproteina b. |
WO2001077077A1 (en) | 2000-04-10 | 2001-10-18 | Novartis Ag | Substituted (hetero)aryl carboxamide derivatives as microsomal triglyceride transfer protein (mtp) and apolipoprotein b (apo b) secretion |
GB0013378D0 (en) | 2000-06-01 | 2000-07-26 | Glaxo Group Ltd | Use of therapeutic benzamide derivatives |
GB0013383D0 (en) | 2000-06-01 | 2000-07-26 | Glaxo Group Ltd | Therapeutic benzamide derivatives |
GB0013346D0 (en) | 2000-06-01 | 2000-07-26 | Glaxo Group Ltd | Therapeutic benzamide derivatives |
US20020032238A1 (en) | 2000-07-08 | 2002-03-14 | Henning Priepke | Biphenylcarboxylic acid amides, the preparation thereof and the use thereof as medicaments |
DE10033337A1 (de) | 2000-07-08 | 2002-01-17 | Boehringer Ingelheim Pharma | Biphenylcarbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
FR2816940A1 (fr) | 2000-11-23 | 2002-05-24 | Lipha | Derives de 4-(biphenylcarbonylamino)-piperidine, compositions les contenant et leur utilisation |
GB0109287D0 (en) | 2001-04-12 | 2001-05-30 | Glaxo Group Ltd | Therapeutic benzamide derivatives |
TNSN03146A1 (fr) * | 2001-06-28 | 2005-12-23 | Pfizer Prod Inc | Indoles, benzofurannes et benzothiophenes a substituant triamide, utiles comme inhibiteurs de secretion de la proteine de transfert des triglycerides microsomaux et/ou de l'apolipo-proteine b (apo b). |
CN1630629B (zh) | 2002-02-28 | 2010-05-05 | 日本烟草产业株式会社 | 酯化合物及其医药用途 |
-
2002
- 2002-05-24 TN TNPCT/IB2002/001876A patent/TNSN03146A1/fr unknown
- 2002-05-24 IL IL15851602A patent/IL158516A0/xx not_active IP Right Cessation
- 2002-05-24 JP JP2003508914A patent/JP4139325B2/ja not_active Expired - Lifetime
- 2002-05-24 WO PCT/IB2002/001876 patent/WO2003002533A1/en active IP Right Grant
- 2002-05-24 SI SI200230732T patent/SI1404653T1/sl unknown
- 2002-05-24 BR BR0210616-7A patent/BR0210616A/pt active Search and Examination
- 2002-05-24 NZ NZ528752A patent/NZ528752A/en not_active IP Right Cessation
- 2002-05-24 DK DK02780923T patent/DK1404653T3/da active
- 2002-05-24 EP EP02780923A patent/EP1404653B1/en not_active Expired - Lifetime
- 2002-05-24 KR KR1020037017167A patent/KR100575919B1/ko not_active IP Right Cessation
- 2002-05-24 AU AU2002307839A patent/AU2002307839B2/en not_active Ceased
- 2002-05-24 GE GE5350A patent/GEP20053720B/en unknown
- 2002-05-24 EE EEP200400040A patent/EE05452B1/xx not_active IP Right Cessation
- 2002-05-24 EA EA200301310A patent/EA007008B1/ru not_active IP Right Cessation
- 2002-05-24 PT PT02780923T patent/PT1404653E/pt unknown
- 2002-05-24 CN CN028130219A patent/CN1522246B/zh not_active Expired - Fee Related
- 2002-05-24 KR KR1020057025027A patent/KR100575944B1/ko not_active IP Right Cessation
- 2002-05-24 CN CN2006100941142A patent/CN1880304B/zh not_active Expired - Fee Related
- 2002-05-24 DE DE60228447T patent/DE60228447D1/de not_active Expired - Lifetime
- 2002-05-24 PL PL02367680A patent/PL367680A1/xx unknown
- 2002-05-24 MX MXPA03011707A patent/MXPA03011707A/es active IP Right Grant
- 2002-05-24 AT AT02780923T patent/ATE405548T1/de active
- 2002-05-24 OA OA1200300327A patent/OA12626A/en unknown
- 2002-05-24 ES ES02780923T patent/ES2307799T3/es not_active Expired - Lifetime
- 2002-05-24 SK SK1610-2003A patent/SK287806B6/sk not_active IP Right Cessation
- 2002-05-24 CA CA002451474A patent/CA2451474C/en not_active Expired - Fee Related
- 2002-05-24 GE GEAP20027236A patent/GEP20063720B/en unknown
- 2002-05-24 RS YUP-1004/03A patent/RS50712B/sr unknown
- 2002-05-24 HU HU0400348A patent/HU229551B1/hu not_active IP Right Cessation
- 2002-05-24 UA UA20031212657A patent/UA75660C2/uk unknown
- 2002-05-24 CZ CZ20033558A patent/CZ20033558A3/cs unknown
- 2002-06-20 US US10/177,858 patent/US6720351B2/en not_active Expired - Fee Related
- 2002-06-21 TW TW091113664A patent/TWI313264B/zh not_active IP Right Cessation
- 2002-06-21 TW TW094146513A patent/TW200628447A/zh unknown
- 2002-06-26 MY MYPI20022415A patent/MY129328A/en unknown
- 2002-06-26 AR ARP020102408A patent/AR036158A1/es active IP Right Grant
- 2002-06-27 PE PE2002000580A patent/PE20030135A1/es not_active Application Discontinuation
- 2002-06-27 AP APAP/P/2002/002567A patent/AP1649A/en active
- 2002-06-27 GT GT200200136A patent/GT200200136A/es unknown
- 2002-06-27 UY UY27360A patent/UY27360A1/es unknown
- 2002-06-28 PA PA20028549301A patent/PA8549301A1/es unknown
-
2003
- 2003-08-13 US US10/639,855 patent/US6949572B2/en not_active Expired - Fee Related
- 2003-08-13 US US10/639,854 patent/US6979692B2/en not_active Expired - Fee Related
- 2003-10-07 ZA ZA200307818A patent/ZA200307818B/en unknown
- 2003-10-09 IS IS6988A patent/IS2603B/is unknown
- 2003-11-17 CR CR7151A patent/CR7151A/es not_active Application Discontinuation
- 2003-12-16 NO NO20035607A patent/NO326700B1/no not_active IP Right Cessation
- 2003-12-17 HR HR20031051A patent/HRP20031051B1/xx not_active IP Right Cessation
- 2003-12-22 BG BG108487A patent/BG108487A/bg unknown
- 2003-12-22 MA MA27457A patent/MA27045A1/fr unknown
- 2003-12-23 EC EC2003004925A patent/ECSP034925A/es unknown
-
2004
- 2004-09-14 HK HK07101214.1A patent/HK1096665A1/xx not_active IP Right Cessation
- 2004-09-14 HK HK04106993.0A patent/HK1064369A1/xx not_active IP Right Cessation
-
2005
- 2005-08-02 US US11/196,563 patent/US7482368B2/en not_active Expired - Fee Related
-
2006
- 2006-02-10 US US11/351,571 patent/US7348355B2/en not_active Expired - Fee Related
-
2008
- 2008-10-13 CY CY20081101126T patent/CY1108407T1/el unknown
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103880797A (zh) * | 2014-03-26 | 2014-06-25 | 沈阳大学 | 苯并呋喃类化合物及其医药用途 |
CN103880797B (zh) * | 2014-03-26 | 2015-12-02 | 沈阳大学 | 苯并呋喃类化合物及其医药用途 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1880304A (zh) | 三酰胺取代的吲哚、苯并呋喃及苯并噻吩 | |
CN1242995C (zh) | 化合物,它们的用途和制备方法 | |
CN1078889C (zh) | 非肽类速激肽受体拮抗剂 | |
CN1297546C (zh) | 带有取代氨甲基的N-(芳基磺酰基)-β-氨基酸衍生物、其制备方法和含有该化合物的药物组合物 | |
CN1259307C (zh) | 酰化的二氢化茚基胺及其作为药物的用途 | |
CN1243723C (zh) | 作为fsad的nep抑制剂的n-苯丙基环戊基取代的戊二酰胺衍生物 | |
CN1016778B (zh) | 螺-取代的戊二酸单酰胺 | |
CN1244575C (zh) | 磺酰基烷酰氨基羟乙氨基磺酰胺逆转录病毒蛋白酶抑制剂 | |
CN101076516A (zh) | 作为丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的硫化合物 | |
CN1213036C (zh) | 新的酰胺类衍生物 | |
CN1238760A (zh) | N-(芳基/杂芳基/烷基乙酰基)氨基酸酰胺类,含有这类化合物的药物组合物,及用这类化合物抑制β-淀粉样肽释放和或合成的方法 | |
CN1173867A (zh) | 吲哚基神经肽y受体拮抗剂 | |
CN1149223C (zh) | 杂环羰基氨基酸羟乙氨基磺酰胺逆转录病毒蛋白酶抑制剂 | |
CN1642599A (zh) | Acc抑制剂 | |
CN1276790A (zh) | 酰胺基噻唑衍生物及其制备方法与药物组合物 | |
CN1659156A (zh) | 新的胍基苯甲酰胺 | |
CN1432022A (zh) | 含有烷基和芳基丙氨酸p2部分的丙型肝炎病毒的大环ns3-丝氨酸蛋白酶抑制剂 | |
CN1040986A (zh) | 环烷基取代的戊二酰胺衍生物的制备 | |
CN101031559A (zh) | 氨基环脲衍生物和其制法及作为激酶抑制剂的医药用途 | |
CN1214339A (zh) | 吡唑衍生物、其制备方法和在药物中的应用 | |
CN1320037A (zh) | 抗病毒的吲哚氧代乙酰基哌嗪衍生物 | |
CN86106984A (zh) | 新的喹唑啉衍生物及其制备方法 | |
CN1527827A (zh) | 治疗性杂环化合物 | |
CN1119856A (zh) | Hiv逆转录酶抑制剂 | |
CN1304406A (zh) | 作为玻连蛋白拮抗剂的杂环甘氨酰β-丙氨酸衍生物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1096665 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1096665 Country of ref document: HK |
|
ASS | Succession or assignment of patent right |
Owner name: PAH AMERICA 15 CO., LTD. Free format text: FORMER OWNER: PFIZER PRODUCTS INC. Effective date: 20130508 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C56 | Change in the name or address of the patentee |
Owner name: ZOETIS P LLC Free format text: FORMER NAME: PAH AMERICA 15 CO., LTD. |
|
CP03 | Change of name, title or address |
Address after: New jersey, USA Patentee after: Zotis P LLC Address before: American New York Patentee before: PAH USA 15 LLC |
|
TR01 | Transfer of patent right |
Effective date of registration: 20130508 Address after: American New York Patentee after: PAH USA 15 LLC Address before: American Connecticut Patentee before: Pfizer Products Inc. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20101124 Termination date: 20150524 |
|
EXPY | Termination of patent right or utility model |